- Home
- ORKA vs NCDL Comparison
ORKA vs NCDL Comparison
Compare ORKA & NCDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORKA
- NCDL
- Stock Information
- Founded
- ORKA 2004
- NCDL 2019
- Country
- ORKA United States
- NCDL United States
- Employees
- ORKA N/A
- NCDL N/A
- Industry
- ORKA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- NCDL
- Sector
- ORKA Health Care
- NCDL
- Exchange
- ORKA Nasdaq
- NCDL NYSE
- Market Cap
- ORKA 354.2M
- NCDL 814.1M
- IPO Year
- ORKA N/A
- NCDL N/A
- Fundamental
- Price
- ORKA $14.67
- NCDL $17.05
- Analyst Decision
- ORKA Strong Buy
- NCDL Hold
- Analyst Count
- ORKA 8
- NCDL 4
- Target Price
- ORKA $39.71
- NCDL $16.63
- AVG Volume (30 Days)
- ORKA 354.5K
- NCDL 249.2K
- Earning Date
- ORKA 08-15-2025
- NCDL 08-06-2025
- Dividend Yield
- ORKA N/A
- NCDL 12.32%
- EPS Growth
- ORKA N/A
- NCDL N/A
- EPS
- ORKA N/A
- NCDL N/A
- Revenue
- ORKA N/A
- NCDL N/A
- Revenue This Year
- ORKA N/A
- NCDL N/A
- Revenue Next Year
- ORKA N/A
- NCDL N/A
- P/E Ratio
- ORKA N/A
- NCDL N/A
- Revenue Growth
- ORKA N/A
- NCDL N/A
- 52 Week Low
- ORKA $5.49
- NCDL $14.21
- 52 Week High
- ORKA $52.32
- NCDL $18.01
- Technical
- Relative Strength Index (RSI)
- ORKA N/A
- NCDL 61.23
- Support Level
- ORKA N/A
- NCDL $16.81
- Resistance Level
- ORKA N/A
- NCDL $17.17
- Average True Range (ATR)
- ORKA 0.00
- NCDL 0.27
- MACD
- ORKA 0.00
- NCDL 0.03
- Stochastic Oscillator
- ORKA 0.00
- NCDL 81.78
About ORKA Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.
About NCDL NUVEEN CHURCHILL DIRECT LENDNG CORP
Nuveen Churchill Direct Lending Corp is a specialty finance company focused predominantly on investing in senior secured loans to private equity-owned U.S. middle market companies. It invest in senior secured loans that typically pay floating interest rates and are senior in the capital structure to junior debt and equity.